Here are four quick notes:
1. Under the agreement, LaunchPad received an exclusive worldwide license from Stryker for this technology, which is covered by four issued and three pending U.S. patents.
2. The technology is based on a unique synthetic biomaterial called Tetranite, which includes the ability to provide immediate fixation of bone to bone and bone to metal.
3. The adhesive technology has been shown to be a non-toxic and effective in multiple animal studies.
4. LaunchPad will seek to commercialize this technology for use in repairing damaged teeth and bones.
More articles on devices:
MIS SI joint fusions: 5 key notes on the NASS coverage recommendation
Materialise partners with Consensus Orthopedics — 4 things to know
Mazor Robotics gets “buy” rating — 6 quick updates
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
